Skip to main content

Table 1 Effects of plant sterol ester capsules on plasma lipid profiles and CRP (n = 16)1

From: The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects

Parameters

Initial Baseline2

Day 7

Day 21

Δ PSE-Placebo

Day 28

Δ PSE-Placebo

Total Cholesterol (mg/dL)

256.0 ± 24.3

     

Placebo phase

 

238.4 ± 18.8

239.3 ± 28.3

 

241.6 ± 27.2

 

Treatment phase

 

239.9 ± 29.6

237.4 ± 29.2

-1.9 (-1%)

230.4 ± 22.3

-11.2 (-5%)

LDL (mg/dL)

177.1 ± 22.8

     

Placebo phase

 

168.5 ± 22.9

169.8 ± 25.6

 

169.4 ± 27.0

 

Treatment phase

 

170.8 ± 27.7

157.8 ± 22.8 A, a

-12 (-7%)

163.3 ± 27.0A

-6.1 (-4%)

HDL (mg/dL)

57.8 ± 19.9

     

Placebo phase

 

50.4 ± 13.8

49.1 ± 13.6

 

51.2 ± 15.4

 

Treatment phase

 

50.8 ± 15.5

53.3 ± 16.3A, a

4.2 (9%)

53.5 ± 16.3a

2.3 (4%)

Triglycerides

125.9 ± 81.4

     

Placebo phase

 

116.6 ± 60.8

122.7 ± 89.0

 

126.5 ± 74.6

 

Treatment phase

 

111.4 ± 69.8

121.7 ± 71.4

-1 (< -1%)

115.7 ± 63.6

-10.8 (-9%)

Total Cholesterol/HDL

4.89 ± 1.64

     

Placebo phase

 

5.1 ± 1.4

5.2 ± 1.6

 

5.1 ± 1.6

 

Treatment phase

 

5.1 ± 1.5

4.8 ± 1.6A, a

-0.4 (-8%)

4.7 ± 1.4A, a

-0.4 (-8%)

LDL/HDL

3.44 ± 1.28

     

Placebo phase

 

3.6 ± 1.3

3.6 ± 1.2

 

3.7 ± 1.2

 

Treatment phase

 

3.7 ± 1.2

3.4 ± 1.2 A, a

-0.2 (-6%)

3.3 ± 1.2A, a

-0.4 (-10%)

CRP (mg/dL)

0.8 ± 0.5

     

Placebo phase

 

0.7 ± 0.4

0.7 ± 0.4

 

0.7 ± 0.5

 

Treatment phase

 

0.8 ± 0.6

0.8 ± 0.5

0.07 (5%)

0.7 ± 0.3

0

  1. 1 Values are means ± SD.
  2. 2 Initial baseline measurement was done 6 week before the placebo phase. Therefore, the data was not included in any analysis, but are provided as reference information
  3. A Significantly different from placebo, p < 0.05 (paired t-test)
  4. a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)